Show results for
Refine by
Glucose Monitoring Articles & Analysis
29 news found
Below are the main microsphere and microneedle solutions provided by CD Formulation: Microsphere and Microneedle Patch Preparation ServicesCD Formulation's research team offers a wide range of microneedle preparations with smooth tip surfaces and clear tip details, for melatonin microneedle patch, parathyroid hormone microneedle patch, exenatide microneedle patch, insulin microneedle patch, and ...
A Flexible Hybrid Electronic Wristband Sensor Platform will be developed to allow for non-invasive blood glucose monitoring, along with other sensing functionality for military personnel,” says Alertgy CEO Marc Rippen. Increased Engineering Capabilities This new location gives Alertgy 2,500 square feet to continue developing ...
ByAlertgy
Alertgy has nearly completed the process of miniaturizing its first generation NICGM® (Non-Invasive Continuous Glucose Monitor) into a smaller form factor that will be the size of modern smart watches. ...
ByAlertgy
How Alertgy is Reinventing the Diabetic Industry Alertgy’s continuous glucose monitor does not require any penetration of the skin, but instead measures blood glucose non-invasively via the newly patented dielectric sensor. ...
ByAlertgy
Alertgy, the biotech startup that’s in the race to be the first company to develop an entirely non-invasive glucose monitoring system is proud to welcome a new hire in the Engineering Department: Benjamin Freer joins Alertgy as Director of Engineering/Principal Sensor Engineer. ...
ByAlertgy
An estimated 415 million people are living with diabetes in the world. Diabetes is a chronic disease, that causes blood sugar levels in your body to become too high, either due to your body not being able to respond properly to insulin or due to your body not being unable to produce any at all. If left untreated, this can lead to serious complications such as heart attack, stroke, obesity, eye ...
Key Research Survey Findings: 52 percent of healthcare providers agreed motivation is a major barrier to patients adhering to blood glucose monitoring compared to only 10 percent of people with diabetes who agreed motivation is a major barrier. ...
ByLifeScan
An article presenting analyses of Continuous Glucose Monitoring (CGM) data from the randomised, placebo-controlled Phase 2b trial DIAGNODE-2 that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd®, has been published in the peer-reviewed scientific journal The Journal of Clinical Endocrinology & Metabolism (JCEM). ...
LifeScan, a world leader in blood glucose monitoring and maker of the iconic OneTouch® brand, today announced that it has named Rekha Ramesh Chief Digital and Information Officer effective immediately. ...
ByLifeScan
The study sponsors used participant data to evaluate the efficiency of local reimbursement policies for insulin pumps and glucose monitors, helping to create more informed and patient-centric policies. ...
Another focus for Diamyd Medical will include developing Continuous Glucose Monitoring (CGM) as an endpoint fit for regulatory approval. As previously communicated and detailed in several peer-reviewed scientific articles, Diamyd® achieves robust statistically and clinically meaningul effects compared to placebo treamtent in both of these endpoints. ...
CDT during the oral presentation session “Glucose Monitoring and Sensing,” which runs from 1:45 to 3:45 p.m. ...
LifeScan, a world leader in blood glucose monitoring and digital health technology, is committed to supporting resources that help promote diabetes education and improved health management, including our most recent sponsorship of The Diabetes Way website, offering a straight-forward educational resource – even for those questions you were afraid to ask. ...
ByLifeScan
Prior to that, while at Abbott he led one of the most successful medical device launches in history with the introduction of the FreeStyle Libre Diabetes Continuous Glucose Monitor system. At the start of his career, Mr. Nock held leadership positions at Danaher and Thermo Fisher Scientific. ...
(NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter and full year ended December 31, 2021. ...
(NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2021 financial results after market close on Tuesday, March 1, 2022. ...
Post-Revita procedure, all patients discontinued their insulin and received only metformin and empagliflozin. Patients were closely monitored for glucose control; pre-specified criteria for insulin re-introduction will be followed to assess for the safety and effectiveness of glucose control. ...
” Since 2018, Valerie Asbury has served as the President and CEO of LifeScan, a global leader in blood glucose monitoring, serving more than 20 million people with diabetes. ...
(NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan (the “Plan”) in accordance with NYSE American Company Guide ...
(NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced operational and financial business updates. ...